Check out your Company Bowl for anonymous work chats.
🚀 Big news! We’re excited to share findings from our Enhanced GLP-1 Care Track members who recently discontinued GLP-1s. On average, participating members experienced virtually no weight gain (-0.1%) four months after discontinuing a GLP-1, compared to an estimated average of 6-7% weight gain from clinical trial data. Read the full press release here: https://lnkd.in/erT8fpT4
How exactly do we evaluate whether virtual healthcare is delivering on its promise? We’re committed to using validated metrics to evaluate clinical outcomes, and we’re always excited to share our success with customers and prospects. ⭐ We’re proud that not only do our cardiometabolic programs improve clinical outcomes within recommended ranges over time, but we employ different study designs to evaluate our programs- including randomized controlled trials and analyses of real-world data. ⭐ Learn more about how we’re evaluating our programs’ value with the American Medical Association’s Return on Health framework: https://lnkd.in/eWUY3hCG
There’s a lot going on at the moment… with our Omada Cares initiative! Our employee volunteer program dedicated to addressing health disparities in communities has helped make a great impact! Last year Omadans collectively contributed: ⚡Over 700 hours volunteering ⚡236 pounds of food donated ⚡26 organizations served We’re looking forward to continuing to make an impact on our community.
💪 Building self-efficacy, or belief in one’s own ability to accomplish a goal, is crucial for long-term success in weight management. Our findings show that participants in a specifically designed GLP-1 program express increased confidence in their ability to lose weight . Want to learn more about how to set the stage for long-term weight health? Check out insights from our ANSWERS initiative: https://lnkd.in/et_kCT7J
GLP-1s have seen unprecedented demand for weight loss treatment in the U.S., but what’s to come globally? Omada Co-Founder and CEO Sean Duffy reflects on the U.S. experience in managing the rise of GLP-1s, and offers five key takeaways as global expansion draws near. What other lessons would you add? Share in the comments.
Curious about the impact AI may have on the diagnostic process in digital health? If so, this is for you. Last year, the National Academies of Sciences, Engineering, and Medicine’s Forum on Advancing Diagnostic Excellence hosted a workshop to discuss the role of AI and digital health technologies throughout the diagnostic process and the impact on the patient experience. Our Chief Privacy and Regulatory Officer Lucia Savage joined the discussions, which highlighted how clinicians may look to safely leverage AI and digital health tools going forward to understand symptoms, improve information gathering and patient–clinician communication, and support clinical decision making. Check out the experts’ perspectives on the matter:
American businesswoman Mary Kay Ash once said, "A company is only as good as the people it keeps.” At Omada, CHRO Nancy Vitale is helping foster a culture that helps attract and keep its people. ❓How does she do it and what led her to Omada? ❓ Check out her engaging interview on the 'Built by People' podcast now! In the episode, Nancy explores her career journey, insights, and experiences in HR:
What clinical and economic lessons can foreign markets learn from the U.S. about GLP-1s? More than you might think. Omada CEO Sean Duffy explored this topic in a piece written in collaboration with the World Economic Forum to coincide with his participation at the annual meeting in hashtag#Davos. Read his takeaways here: https://lnkd.in/ezDVprbp
Weight management is not just about numbers on a scale; it's a deeply personal journey that can be fraught with emotional hurdles. That’s why we want to understand our member experience. In a recent Omada Insights Lab analysis, our team found that many members discontinue taking GLP-1s for weight loss due to access barriers, not because they achieved their goal weight. How can we support these members? We found they want a highly specialized companion program that provides human support and behavioral health content. Learn more: https://lnkd.in/eMaRwkhf
New Proof Points edition, and new location! Omada’s clinical newsletter has moved to our company account. In our first edition of the year, Omada Clinical Research Scientist Susan Devaraj PhD, RD reflects on early GLP-1 outcomes data from Omada Insights Lab, and the importance of redefining success in GLP-1 treatment programs. Dive in, share and subscribe!
